Milder chemo before TIL therapy shows promise for tough-to-treat melanoma
NCT ID NCT06151847
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether a reduced dose of chemotherapy drugs (fludarabine and cyclophosphamide) given before infusing a patient's own tumor-fighting immune cells (lifileucel) could work for advanced melanoma that has spread or can't be removed. Eleven adults with stage IIIC or IV melanoma took part. The goal was to see if the milder prep still allows the immune cells to attack the tumor effectively while possibly causing fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lifileucel (tumor-infiltrating lymphocytes) with reduced-dose fludarabine, cyclophosphamide, and interleukin-2
- What this could lead to
- If successful, this could show that a milder chemotherapy prep before TIL therapy is still effective for metastatic melanoma, potentially reducing side effects.
- What could go wrong
- This is a very small, early-phase trial (11 people) with no control group. Results may not apply broadly, and TIL therapy carries risks like severe immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Kansas Cancer Center
Kansas City, Kansas, 66160, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug cocktail targets rare, aggressive melanoma